Evidence map›Paper›PMID 37270580›Full record

ArticleCell death and differentiation2023

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer.

Paul Miller, Elliot H Akama-Garren, Richard P Owen, Constantinos Demetriou, Thomas M Carroll, Elizabeth Slee, Khatoun Al Moussawi, Michael Ellis, Robert Goldin, Eric O'Neill and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death and differentiation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Paul MillerLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. paul.miller@ludwig.ox.ac.uk.ORCID 0000-0002-5800-1220
Elliot H Akama-GarrenLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0002-1690-2055
Richard P OwenLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Constantinos DemetriouDepartment of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.
Thomas M CarrollLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Elizabeth SleeLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Khatoun Al MoussawiLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.
Michael EllisLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK.ORCID 0000-0003-2613-7673
Robert GoldinCentre for Pathology, Department of Medicine, Imperial College London, London, W2 1NY, UK.ORCID 0000-0001-5184-4519
Eric O'NeillCentre for Pathology, Department of Medicine, Imperial College London, London, W2 1NY, UK.
Xin LuLudwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. xin.lu@ludwig.ox.ac.uk.
University of Oxford · GBImperial College London · GB

Funding

Medical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0M
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7M
NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM144273Wellcome Trust
6 · The paper itself

Abstract

Oncogenic KRAS activation, inflammation and p53 mutation are key drivers of pancreatic cancer (PC) development. Here we report iASPP, an inhibitor of p53, as a paradoxical suppressor of inflammation and oncogenic KRAS

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAnimalsCarcinogenesisCell Transformation, NeoplasticInflammationIntracellular Signaling Peptides and ProteinsMiceMice, NudeProto-Oncogene Proteins p21(ras)Repressor ProteinsSignal TransductionTumor Suppressor Protein p53Hras protein, mouseIntracellular Signaling Peptides and ProteinsPpp1r13l protein, mouseProto-Oncogene Proteins p21(ras)Repressor ProteinsTumor Suppressor Protein p53

Identifiers

PMID37270580
PMCPMC10307949
OpenAlexW4379259058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.